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ABSTRACT
Introduction: Pseudobulbar affect (PBA) is 
characterized by involuntary and uncontrollable 
laughing and/or crying episodes, occurring 
secondary to neurological disease or injury. 
The impact of PBA on social and occupational 
function, health status, quality of life (QOL), and 
quality of relationships (QOR) is not well studied.
Methods: This US survey conducted by Harris 
Interactive compared health status and daily 
function of patients with and without PBA. 
Eligible respondents were Harris Panel 
Online registrants previously diagnosed with 
stroke, multiple sclerosis, Parkinson’s disease, 
Alzheimer’s disease, traumatic brain injury, 
or amyotrophic lateral sclerosis, or primary, 
nonpaid caregivers for such patients who were 
too debilitated to participate. PBA was identified 
by a Center for Neurologic Study lability scale 
score of 13 or greater. Measures included the 
36-item short form health survey (SF-36), the 
work productivity and impairment (WPAI) 
questionnaire, visual analog scales (VAS) for 
impact of PBA symptoms on QOL and QOR, 
and customized questions related to burden and 
impact of involuntary laughing/crying episodes 
on patients’ lives. Survey responses were 
weighted to adjust for the relative proportion 
of the primary neurological conditions in 
the overall population and between group 
differences in patient age and gender. PBA and 
non-PBA group responses were compared using 
two-tailed t tests adjusted for severity of the 
primary neurological conditions.
Results: The 1,052 respondents included 
399 PBA group participants and 653 controls. 
The PBA group showed significantly worse 
scores versus non-PBA controls on component 
and summary SF-36 scores (P < 0.05 for all), 
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to inconsistency and confusion in the literature. 
PBA is used in this paper; however, other 
commonly used terms have included pathological 
laughing and crying, affective lability, emotional 
incontinence, emotional lability, and involuntary 
emotional expression disorder.
PBA may cause severe distress, embarrassment, 
and social disability for patients [1, 3, 6–9]; 
however, the burden of illness associated 
with PBA is not well characterized. Studies in 
populations with stroke, PD, and other movement 
disorders have shown that patients with PBA or 
similarly described symptoms of inappropriate 
laughing and/or crying have a greater incidence 
of depression [10, 11] and decreased executive 
function [12], sexual function [13], and ability 
to perform activities of daily living (ADL) [14] 
compared with patients with the same underlying 
neurological disorder but without PBA symptoms.
Patients can be screened for PBA using 
the Center for Neurologic Study lability scale 
(CNS-LS). The CNS-LS is the first self-report 
measure of PBA to be described, and has been 
validated in ALS [15] and MS [16] patients. The 
CNS-LS consists of subscales for laughter (four 
items) and for tearfulness (three items), with 
each item scored on a 5-point scale (1, applies 
never; 5, applies most of the time) for a total score 
ranging from 7 (no symptoms) to 35 (maximum). 
In patients with ALS (n = 99), a CNS-LS score of 
13 or greater correctly predicted neurologists’ 
diagnoses of PBA for 82% of patients (sensitivity 
of 0.84; specificity of 0.81); the CNS-LS also 
showed good test-retest reliability (0.88) and 
internal consistency (Cronbach’s α coefficient 
0.87) [15]. In patients with MS (n = 90), a 
CNS-LS score of 13 or greater correctly predicted 
physicians’ diagnoses of PBA for 78% of patients 
(sensitivity of 0.96; specificity of 0.55), and a 
CNS-LS score of 17 or greater correctly predicted 
89% of physicians’ diagnoses (sensitivity of 0.94; 
specificity of 0.83) [16].
VAS scores (P < 0.05 for both), and WPAI scores 
(P < 0.05). Among PBA group respondents, PBA 
contributed a great deal to or was the main cause 
of patients becoming housebound for 24% and 
being moved to supervised living placement for 
9% of respondents.
Conclusion: PBA is associated with considerable 
burden incremental to that of the underlying 
neurological conditions, affecting QOL, QOR, 
health status, and social and occupational 
functioning.
Keywords: Burden of illness; Health status; 
Occupational function; Pseudobulbar affect; 
Quality of life; Social function
INTRODUCTION
Pseudobulbar affect (PBA) is a neurological 
disorder characterized by involuntary, sudden, 
and frequent episodes of laughing and/or 
crying that are typically out of proportion or 
incongruent to the underlying emotional state 
[1–4]. Although the etiology of PBA is not 
completely understood, it is strongly associated 
with neurological disease or injury that affects 
the frontal lobes and descending pathways to 
the brainstem, basis pontis, and cerebellum, 
and its symptoms appear to be similar across 
different patient populations [1–3]. PBA has 
been reported secondary to a wide variety of 
neurological conditions; available prevalence 
data suggest that neurological conditions 
commonly associated with PBA include 
Alzheimer’s disease (AD) and other dementias, 
amyotrophic lateral sclerosis (ALS), multiple 
sclerosis (MS), Parkinson’s disease (PD), stroke, 
and traumatic brain injury (TBI) [2, 3, 5].
Partly owing to different preferences across 
physician specialties, a variety of terms have 
been used to describe syndromes of inappropriate 
laughing and/or crying, and this has contributed 
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inclusion in recent PBA clinical trials [17–19]. The 
online survey was fielded between January 27, 
2006 and March 31, 2006. The average survey 
length was 18 minutes.
Survey Sample
Survey participants were recruited in two waves. 
To recruit the PBA group, invitations were first 
sent to 857 members of the Harris Panel Online 
(HPOL) sample, who had voluntarily agreed 
to participate in various HI online research 
surveys, had participated in the previous PBA 
prevalence survey, and had scored 13 or more 
on the CNS-LS in that survey, suggestive of 
PBA. To complete recruitment of the PBA 
group and to recruit the controls, invitations 
were then sent to a nationally representative 
sample of more than 6 million US adults (aged 
18 years and over), registered in the HPOL, in 
a similar fashion to the recruitment procedure 
for the previous PBA prevalence survey [5]. At 
the time of recruitment, the HPOL included 
approximately 1.5 million individuals who had 
been screened by HI by means of a checklist for 
the presence of chronic illnesses. HPOL panel 
members previously identified by HI as either 
having AD, ALS, MS, PD, and stroke or being 
primary, nonpaid caregivers for a household 
member with one of these conditions were sent 
online invitations to participate in a survey 
about their “thoughts on and experiences with 
some important healthcare-related topics” [5]. 
To enhance the representativeness of the total 
sample, invitations were also sent to a randomly 
selected national sample from the general HPOL. 
Recruitment quotas were set for each underlying 
condition in order to have a large enough 
sample of each disease group for analysis.
The HI chronic illness screener instrument did 
not include patients with TBI [20]. To identify and 
recruit patients with TBI, survey invitations were 
The authors have recently published the 
results of a survey conducted using the CNS-LS 
to estimate the prevalence of PBA in the USA 
across six commonly associated underlying 
conditions: AD and other dementias, ALS, MS, 
PD, stroke, and TBI [5]. Adopting a conservative 
CNS-LS cutoff score of 21 or greater yielded an 
overall prevalence of 9.4%, which translated 
to 500,000 to 2 million individuals in the USA 
with PBA. With a lower CNS-LS threshold of 
13 or greater, which helps identify less severely 
affected patients with a reasonable sensitivity 
and specificity, the prevalence was even higher 
(37.5%), or a total of 1.8–7.1 million individuals.
The authors report the results of a follow-on 
survey to estimate the impact, or burden of 
illness, of PBA on general health status and 
overall functionality by comparing measures of 
general health, social and occupational function, 
quality of life (QOL), and other measures in 
patients and caregivers for patients with AD, 
ALS, MS, PD, stroke, and TBI with and without 
PBA symptoms.
MATERIALS AND METHODS
This study was commissioned by Avanir 
Pharmaceuticals and conducted online by Harris 
Interactive® (HI, New York, New York, USA) 
a market research firm specializing in public 
opinion and consumer surveys. The survey was 
designed and directed by Avanir Pharmaceuticals 
and statistical analysis and study design specialists 
from HI and Cerner Health Insights. The survey 
sample included patients with PBA symptoms or 
primary, nonpaid caregivers of patients with PBA 
symptoms to answer for patients unable to do so 
themselves, and thus ensure participation of more 
severely incapacitated patients. For purposes 
of the study, PBA symptoms were defined as 
a CNS-LS score of 13 or greater based on the 
minimum CNS-LS baseline score required for 
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sent to panel members with chronic headaches, 
posttraumatic stress disorder, or general disability. 
The survey asked these members whether they 
had been diagnosed with TBI by a physician or 
other healthcare professional, defined as a head 
injury requiring hospitalization, which resulted 
from being knocked unconscious, having a skull 
fracture, or having other brain injury. Because 
US data show that only approximately 16% of 
TBI survivors each year are hospitalized for their 
injury, the TBI patients participating in this study 
probably represented a subset of relatively severe 
cases [20].
The survey invitations were identical for all 
invitees, i.e., the invitations that were sent to 
HPOL members who had participated in the 
previous prevalence survey did not reference 
that survey or the participants’ previous 
participation. Invitations included a unique 
log-in name and password to confirm that the 
person responding was the selected participant. 
Selection of the ultimate sample for each 
primary condition was designed to include a mix 
of responses from patients and caregivers, with 
target proportions of two-thirds patients and 
one-third caregivers in both the PBA and control 
groups. Numeric quotas were assigned to each 
disease group and proportion of respondents 
with PBA and without PBA within each disease 
group. The online program assigned respondents 
into each quota group based on survey logic.
Identification of Patients with PBA and 
Matched Controls
Eligible respondents (those confirmed to 
be patients or primary, nonpaid caregivers 
for patients with one of the six designated 
conditions) completed an online CNS-LS [15, 16]. 
Patients and caregivers were asked the same 
screening questions, with caregivers answering 
based on their observations of the patient. 
Respondents with a CNS-LS score of 13 or greater 
were assigned to the PBA group; respondents 
with a CNS-LS score less than 13 were assigned 
to the control group. The control (non-PBA) 
participants were included to discern the burden 
of PBA incremental to other problems stemming 
from the primary neurological disease. Once the 
survey program assigned each respondent to 
either the PBA or non-PBA group, respondents 
continued through the remainder of the survey.
Burden of Illness Measures
In order to measure various aspects of burden of 
illness in PBA group respondents and controls, 
a series of medically validated scales was 
administered, including the 36-item short form 
health survey (SF-36), the work productivity 
and activity impairment (WPAI) questionnaire: 
general health V2.0, the screen for caregiver 
burden (SCB), the Center for Epidemiologic 
Studies depression scale 10-item short form 
(CES-D10), and visual analog scales (VAS) for 
QOL and quality of relationships (QOR).
The SF-36 health survey is a 36-question 
self-reported measure that rates general health 
and well-being across eight domains, which 
are summarized into physical and mental 
health component measures. Scores for each 
domain and the summary physical and mental 
health component measures are transformed 
into scores of 0–100 (0, worst health; 100, best 
health) [21]. The WPAI questionnaire measures 
employment and rates of absenteeism, reduction 
in work productivity, and impairment in 
regular daily activities other than working, 
during the previous 7 days [22]. The SCB 
probes the prevalence and associated distress of 
25 potentially negative experiences of caregiving 
[23]. The SCB yields two scores. The objective 
score (0–25) counts the presence of experiences 
from a list of 25 burdens, such as “I am upset 
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that I cannot communicate with my patient,” 
“I feel so alone, as if I have the world on my 
shoulders,” and “I am embarrassed to take my 
patient out for fear he/she will do something 
bad.” The subjective score (25–100) indicates 
the degree of distress associated with each item 
(1, “no occurrence” or “occurrence, but no 
distress;” 2, “mild distress;” 3, “moderate distress;” 
or 4, “severe distress”). The CES-D10 scale is a 
screening test for depression with each item 
scored from 0 to 3 (scoring range of 0–30), and 
with a validated cutoff score of 10 or greater for 
clinically meaningful depressive symptoms [24]. 
VAS for QOL and QOR asked patients to indicate 
“the degree to which uncontrollable laughter, 
tearfulness, or anger” had affected the overall 
QOL and the overall QOR during the past week, 
by making a mark on a horizontal line with 
anchors of “0, not at all” on the left and “100, 
continuously” on the right.
In addition to the above scales, specific 
questions were asked to assess the emotional 
state of the patients over the past week, the 
frequency, burdensomeness, and emotional 
impact of involuntary laughing and/or crying 
episodes, and the degree to which these episodes 
disrupted specific life activities. For example, 
respondents were asked the degree to which 
episodes of involuntary laughter or crying 
interfered with activities such as spending time 
Table 1  Summary of scales: who responded and from which perspective
Scale Caregiver perspective Patient perspective
Completed by both the PBA and control group respondents
CNS-LS As patient proxy Self-rating
Disease severity Caregiver opinion of 
patient’s disease severity
Self-rating
SF-36 As patient proxy Self-rating
CES-D10 Caregiver self-rating Self-rating
WPAI questionnaire Caregiver self-rating Self-rating
Caregiver burden Caregiver self-rating ND
VAS QOL/QOR ND Self-rating
Customized questions related to negative emotional feelings Caregiver opinion of 
patient’s feelings
Self-rating
Completed by only PBA group respondents
Customized questions related to laughing/crying episode frequency, 
severity, and impact
Caregivers in consideration 
of patients’ episodesa
Self-ratinga
CES-D10 Center for Epidemiologic Studies depression scale 10-item short form, CNS-LS Center for Neurologic Study 
lability scale, ND not determined, PBA pseudobulbar affect, QOL quality of life, QOR quality of relationships, SF-36 36-
item short form health survey, VAS visual analog scale, WPAI work productivity and activity impairment questionnaire: 
general health V2.0
a Customized questions related to laughing and crying episodes were only answered by PBA group patients and caregivers 
who also answered “yes” to the question, “Have you [has the patient you care for] experienced involuntary episodes of crying 
and/or laughing that were exaggerated or even contrary to how you [your patient] felt at the time?”
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with friends and family, dining out, or going to 
the movies; the degree to which episodes caused 
them to feel frustrated, isolated, embarrassed, 
or were a problem for those around them, and 
the extent to which episodes contributed to life 
situations such as becoming housebound, losing 
a job, severing close relationships, or moving to 
supervised living.
Both patients and caregivers in the PBA 
and control groups completed the SF-36, with 
questions for caregivers adjusted to instruct them 
to respond on behalf of the patient (caregivers 
responded as patient proxies). Patients and 
caregivers rated themselves individually on 
the CES-D10 scale and the WPAI questionnaire 
(caregivers answered on their own behalf). Only 
patients (caregivers were not used as patient 
proxies) responded to the VAS QOL and QOR 
questions. Only caregivers responded to the SCB. 
Only the PBA group patients and caregivers (no 
controls) answered the customized questions 
related to the frequency, burdensomeness, and 
impact of PBA episodes, with caregivers answering 
these questions on behalf of their patients. Table 1 
provides a summary of the scales and respondents.
Control for Underlying Disease Severity
In order to account for the impact of potential 
differences in underlying disease severity on 
results, respondents were asked to self-rate 
the severity of their/their patient’s underlying 
disease in response to a single question: “In your 
opinion, how would you classify the severity 
of your/your patient’s [condition]?” The given 
choices were mild, moderate, or severe. Based 
on the responses to this question, weighting 
multipliers were added to survey responses 
within each primary disease group of PBA and 
control respondents to adjust for disease severity.
As a sensitivity measure, respondents were 
also administered, established, and validated 
severity scales designed for individual diseases, 
including the ALS functional rating scale (ALS-
FRS) for ALS patients [25], the Schwab and 
England ADL scale [26] for MS, PD, stroke, and 
TBI, and the instrumental ADL (IADL) scale [27] 
for AD patients. The respondent scores on the 
Schwab and England and IADL scales were then 
correlated with the respondent self-ratings of 
disease severity (mild, moderate, or severe) to 
validate the self-ratings; correlations were not 
done for the ALS group due to the multiple 
outputs of the ALS-FRS as well as the small 
sample of ALS patients.
Demographic Weighting
To adjust for demographic differences between 
the PBA and control groups, weighting 
multipliers were applied to PBA and control 
respondent data by disease group to make them 
more similar to each other in terms of age and 
gender (when sample size was sufficiently large) 
to minimize variation in responses that might be 
attributable to these demographic characteristics. 
This was not possible for the AD and ALS disease 
groups. The number of AD and other dementias 
patient respondents was too small to apply 
an adjustment because, due to the disabling 
nature of the disease, 90% of the AD and 
other dementias respondents were caregivers. 
The number of ALS patient respondents was 
also too small to apply an adjustment due to 
difficulties with recruitment stemming from the 
low prevalence of this condition in the overall 
population. All “unweighted” respondents were 
given a demographic weight of 1.0.
To adjust for the relative proportions of 
the six underlying conditions within the 
total US population (including the estimated 
prevalence of PBA within each condition), and 
thus increase generalizability to the total US 
patient population, additional post weights were 
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applied to all outcomes reported for the total 
study population across PBA/control and disease 
subgroups (Table 2) [5].
Margin of Sampling Error
In a random probability sample of respondents, 
study results are subject to a margin of sampling 
error, which is calculated using the size of the 
sample. Although the sample in this study 
was not a random probability sample in its 
true sense, because any Internet panel is made 
up of those who self-select to join, margins 
of error were calculated and are provided for 
general reference in interpreting the survey 
results. Assuming a 95% confidence interval for 
statistical testing across the board, the margin 
of error was ±4.9% for the total PBA group and 
±3.8% for the non-PBA group. For individual 
disease states within the PBA group, the margin 
of error was 18.9% for the ALS group and ranged 
from ±11.1% to 12% for the other disease states; 
for the non-PBA group, the margin of error was 
30.2% for the ALS group and ranged from ±8% 
to 9.6% for the others.
Significance Tests
Two group t tests were conducted to test for 
mean differences in study measures between the 
PBA and control groups and within each disease 
state. All significance testing was performed at 
the 95% confidence interval, two tailed. These 
tests were performed after all other weighting 
(as described above) was applied to the data. 
The severity weights were used to validate the 
statistical significance of differences, and all 
reported P values in the article reflect adjustment 
for disease severity; however, numerical results 




Of 857 patients/caregivers of patients with 
a CNS-LS score of 13 or greater from the 
initial HPOL prevalence survey [5] who were 
recontacted in the first wave of recruitment 
for this survey, 599 (70%) responded, of whom 
Table 2  Disease group proportions in study population and weighting to relative US disease prevalence







AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis, CNS-LS Center for Neurologic Study lability scale, MS multiple 
sclerosis, PBA pseudobulbar affect, PD Parkinson’s disease, TBI traumatic brain injury
a Relative proportion of respondents with each primary disease in the current survey
b The weighted proportions represent the estimated relative proportions of patients with PBA among underlying illnesses in 
the US population. These were calculated by taking the estimated number of patients in the USA with each of the underlying 
diseases, and then estimating the number of patients with PBA symptoms (CNS-LS ≥13) within each disease state and dividing 
by the total number of US patients estimated to have PBA (number of patients with CNS-LS ≥13 using prevalence source 1 [5])
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453 were still qualified to participate (had 
the diagnosis in question or remained the 
primary, nonpaid caregivers of such a patient) 
and completed the CNS-LS screener. A total of 
341 (75%) of these 453 still had a CNS-LS score 
of 13 or greater, and 285 of these participated 
in the present survey as part of the PBA group; 
the remaining 56 respondents with a CNS-LS 
score of 13 or greater did not participate, as 
their disease quotas were already full. For the 
remaining recruitment, a random sample 
(n = 27,696) of the HPOL database previously 
identified as having ALS, AD or other dementias, 
MS, PD, stroke, or symptoms suggestive of TBI 
were invited to participate. Of the 9,283 (34.5%) 
individuals who responded, 2,499 (26.9%) were 
found eligible (patient or primary, nonpaid 
caregiver with one of the disease states of interest 
and completed the online CNS-LS screen). Of 
these 2,499 individuals, 767 participated in the 
survey and 1,732 were qualified but did not 
participate, as the quotas for their disease states 
were already full.
Therefore, in total 1,052 respondents 
completed the survey; 399 (37.9%) fulfilled 
the criteria for PBA (CNS-LS score ≥13) and 
653 (62.1%) comprised the non-PBA (CNS-LS 
score <13) control group (Table 3). In the PBA 
group, 66.4% were patients and 33.6% were 
caregivers, and in the control group, 63.3% were 
patients and 36.7% were caregivers (Table 3). 
Recruitment did not meet the quota for the ALS 
group. The goal of achieving proportions of 
two-thirds patients and one-third caregivers was 
achieved for most diseases in the PBA group, but 
not for the control group, most notably for ALS, 
which comprised only 11 controls including 
four patients (36%) and seven caregivers (64%), 
and AD and other dementias, which comprised 
8% patients and 92% caregivers (Table 3).
Demographic characteristics are provided in 
Table 4. The mean patient age was 55.5 years 
in the PBA group and 61.8 years in the control 
group; patients with TBI, ALS, and MS were 
generally younger than those with stroke, PD, 
and AD. Fifty-eight percent of the PBA group 
Table 3  Survey respondents by primary conditiona
Primary condition PBA groupb Control groupc
Patients Caregivers Totals Patients Caregivers Totals
n (%) n (%) n n (%) n (%) n
ALS 19 (68) 9 (32) 28 4 (36) 7 (64) 11
AD/dementia 42 (63) 25 (37) 67 9 (8) 104 (92) 113
MS 53 (68) 25 (32) 78 120 (81) 29 (19) 149
PD 50 (67) 25 (33) 75 73 (58) 52 (42) 125
Stroke 51 (67) 25 (33) 76 117 (78) 34 (22) 151
TBI 50 (67) 25 (33) 75 90 (87) 14 (13) 104
Total 265 (66) 134 (34) 399 413 (63) 240 (37) 653
AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis, CNS-LS Center for Neurologic Study lability scale, MS multiple 
sclerosis, PBA pseudobulbar affect, PD Parkinson’s disease, TBI traumatic brain injury
a Respondents consisted of patients or primary, nonpaid caregivers of patients
b The PBA group was defined by a score of 13 or greater on the CNS-LS
c Controls were patients (or caregivers of a patient) who scored less than 13 on the CNS-LS
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patients and 57% of the control group patients 
were women, with the lowest percentages in the 
ALS and TBI groups and the highest percentage 
in the MS group. Fewer PBA group patients 
(7%) than control patients (21%) were living 
independently; however, most patients lived 
with their caregivers (74% PBA group; 65% 
non-PBA controls). Overall, most caregivers 
were spouses (34% PBA group; 44% non-PBA 
controls) or children (38% PBA group; 34% non-
PBA controls) of the patients for whom they 
provided care.
The mean (median; range) baseline CNS-LS 
scores were 18.75 (18; 13–35) in the PBA group 
and 9.17 (9; 7–12) in the control group. Of the 
PBA group respondents, 30.4% had a CNS-LS 
score of 21 or greater, indicative of more 
moderate to severe PBA. PBA group patients 
(72%) were significantly more likely than 
controls (45%) to have been diagnosed with 
any of the following psychiatric conditions 
along with their primary neurological condition: 
depression (52% vs. 28%), anxiety/panic 
attacks (43% vs. 17%), bipolar disorder (13% 
vs. 4%), posttraumatic stress disorder (20% 
vs. 11%), psychotic disorder (9% vs. 1%), or 
schizophrenia/delusional disorder (5% vs. 2%) 
(P < 0.05 for overall prevalence of a psychiatric 
diagnosis and for each diagnosis). The degree to 
which the greater prevalence of these diagnoses 
in the PBA group may represent a misdiagnosis 
of PBA symptoms is unclear and is not able to be 
determined from the survey.
While the majority of respondents assessed 
the severity of their/their patients’ primary 
neurological disease as mild or moderate (Table 4), 
significantly more PBA respondents in the PD 
(13% PBA vs. 3% controls) and stroke (18% 
PBA vs. 7% controls) groups rated their/their 
patients’ condition as severe (P < 0.05 for both). 
On the validated disease-specific severity scales, 
PBA group respondents with MS, PD, stroke, 
and TBI scored significantly lower (indicating 
greater severity) on the Schwab and England 
ADL scale than non-PBA control respondents 
with the same conditions (P < 0.05). Among 
patients with AD, mean scores on the IADL 
scale were similar between the PBA and control 
group patients (15.0 and 14.4, respectively). 
The sample size of patients with ALS (n = 48) 
was too small to assess for significance between 
the PBA and control groups on the ALS-FRS; 
however, no clear numerical differences were 
observed in the various components of this 
scale (bulbar symptoms, upper and lower limbs, 
and breathing).
The respondent self-ratings of global 
disease severity showed significant correlation 
(P < 0.01; Pearson product-moment correlation) 
to the disease-specific scales for AD (r = −0.66), 
MS (r = 0.66), PD (r = 0.54), and stroke (r = 0.32), 
suggesting that the respondent self-ratings were 
a valid measure of disease severity. Although the 
correlation for TBI (r = 0.11) was not significant, 
this may be reflective of low variation in 
responses for the global self-assessment in this 
group (>60% said moderate).
General Health Status
Respondents screening positive for PBA (CNS-LS 
score ≥13) had significantly lower (worse) scores 
on all eight domains, as well as the physical 
and mental component scores, of the SF-36 
compared with respondents in the non-PBA 
control group (CNS-LS score <13) (Fig. 1). The 
adjusted mean physical component summary 
and mental component summary scores were 
35.0 and 34.4, respectively, for the PBA group 
respondents, compared with 39.1 and 42.5, 
respectively, for the non-PBA controls (P < 0.05) 
(Fig. 1). The between-group differences were 
generally larger for the mental health domain 
items than for the physical health domain items, 
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as well as the mental component summary; the 
PBA group also scored significantly worse than 
the non-PBA controls within each disease group 
except ALS (P < 0.05).
Impact of PBA Symptoms on QOL and QOR
VAS measurements demonstrated a significantly 
larger negative impact of uncontrollable 
laughter, tearfulness, or anger on PBA group 
patients’ overall QOL and QOR during the 
past week (37.9 and 37.0, respectively) versus 
controls (12.3 and 10.4, respectively; P < 0.05 
[Fig. 2]). The differences in VAS QOL and 
QOR scores were also significant for all disease 
subpopulations (P < 0.05) with the exception 
of the QOL measure in ALS patients (n = 23), 
among whom the mean scores were 46.3 for the 
PBA group and 15.3 for the controls; however, 
the number of ALS control patients (n = 4) was 
too small to provide a reliable result.
The QOL and QOR scores correlated highly 
with the mental component summary of 
the SF-36 (r = −0.55 and −0.61, respectively), 
supporting the hypothesis that the VAS and 
the mental domains of the SF-36 are measuring 
a similar construct. QOL and QOR were not 
highly correlated with the physical component 
summary of the SF-36 (r = −0.18 and −0.14, 
respectively), thus not supporting construct 
validity for the QOL and QOR measuring a 
physical construct.
The WPAI Questionnaire
The PBA group patients and caregivers 
were less likely to be employed for pay, 
and experienced greater work and activity 
impairment than the control group patients 
and caregivers (Table 5). Among patients, 
significant differences over the previous 
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SF-36 mental health domains
Fig. 1  SF-36 mean physical (a) and mental health (b) domain and component summary scores. The mean scores are adjusted 
for demographic differences; P values are calculated with adjustment for underlying disease severity. * P < 0.05 independent 
samples two-tailed t test. PBA pseudobulbar affect, SF-36 36-item short form health survey
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and non-PBA control groups in the rate of 
workplace absenteeism (P < 0.05), overall 
work impairment/productivity loss (P = 0.05), 
and overall impairment in daily activities 
outside of work (P < 0.05) due to the 
patients’ health problems. Among caregivers, 
significant differences were observed between 
the PBA and non-PBA control groups in 
the degree to which their patients’ health 
problems affected caregiver productivity 
while at work (presenteeism) and overall work 
impairment/productivity loss. However, there 
were no significant differences between the 
PBA and control group caregivers in terms of 
employment status, workplace absenteeism, 
and nonwork activity impairment.
Depression: Patient Respondents
Most patients in the PBA group and over half 
in the control group had significant depressive 
symptoms as determined by a CES-D10 scale 
score of 10 or greater (87% PBA group vs. 56% 
controls; P < 0.05). Within the individual disease 
categories, 74% of the PBA group patients 
with ALS and 82–89% in the other disease 
categories exceeded this CES-D10 threshold 
versus a range of 38−75% among controls 
across all disease categories. The prevalence of 
depressive symptoms (CES-D10 scale score ≥10) 
was significantly higher in the PBA versus the 
control group patients in the MS, PD, stroke, 
and TBI disease groups (P < 0.05). While rates 
of depressive symptoms were also higher among 
the PBA group patients with AD and ALS than 
among controls with the same diseases, the 
differences were less pronounced and the disease 
subgroups were too small for these differences to 
reach statistical significance.
Given the high frequency of depressive 
symptoms observed among PBA group patients, 
and previous research showing that the presence 
of such symptoms may significantly affect SF-36 
scores [28], a post hoc multivariate analysis 
of variance (MANOVA) was performed to 
determine the impact of PBA group assignment, 
depression, and their interaction on SF-36 scores. 
This approach compares the mean SF-36 domain 
score for each of the four types of respondents: 
PBA group respondents with depression; 
PBA group respondents without depression; 
control group respondents with depression; 
and control group respondents without 
depression. In addition, the analysis takes into 
account the fact that the same variables (PBA 
and depression) are being tested many times. 
Only patient respondents were included in 
this analysis as caregiver respondents answered 

























PBA group (n = 265)
Control group (n = 413)
QOL QOR
Fig. 2  Adjusted mean PBA and non-PBA control group 
visual analog scale (0–100) scores. Patients were asked to 
mark on horizontal lines with anchors of “not at all” at the 
leftmost position (“0”) and “continuously” at the rightmost 
position (“100”) how much episodes of uncontrollable 
laughter, tearfulness, and anger have affected their overall 
QOL and their overall QOR with others during the 
past week. Mean scores are adjusted for demographic 
differences; P values are calculated with adjustment for 
underlying disease severity. * P < 0.05 independent samples 
two-tailed t test. Patients rated QOL and QOR on their 
own behalf (caregivers did not serve as patient proxies for 
these measures). PBA pseudobulbar affect, QOL quality of 
life, QOR quality of relationships
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instead of as patient proxies. The MANOVA 
analysis demonstrated a significant main effect 
of depression (CES-D ≥10) on all SF-36 domains, 
and of PBA group assignment (CNS-LS ≥13) on 
all SF-36 domains except bodily pain and the 
physical component summary. An interaction 
of depression and PBA group assignment was 
seen for the SF-36 domains of role physical, 
role emotional, mental health, and the mental 
component summary with depression reducing 
the impact of PBA group assignment on these 
domains (Table 6).
Depression: Caregiver Respondents
Depressive symptoms (CES-D10 scale score ≥10) 
were also present in most caregivers and occurred 
with similar overall frequency in the PBA and 
control groups (73% and 71%, respectively). 
Within disease subgroups, significantly more 
control group caregivers of patients with AD 
and other dementias experienced depressive 
symptoms (79%) compared with their PBA 
group counterparts (56%), whereas significantly 
more PBA group caregivers for patients with PD 
(68%) and TBI (91%) experienced depressive 
symptoms compared with controls (33% and 
43%, respectively; P < 0.05 for all).
Screen for Caregiver Burden
Mean total scores on the SCB suggested that the 
overall burden of caring for patients in the PBA 
group was slightly but significantly higher than for 
the control group. Both the objective (prevalence) 
and subjective (distress) scores were higher among 
caregivers in the PBA group (13.7 and 41.5, 
respectively; P = 0.05) compared with the control 
group (10.2 and 37.6, respectively; P = 0.05).
Impact on Feelings and Activities
Significantly higher percentages of patients 
(including caregivers rating as patient proxies) 
in the PBA group than in the non-PBA control 
group reported negative emotional feelings in 
Table 5  Mean work productivity and activity impairment questionnaire scoresa
Parameter Patients (N = 678) Caregivers (N = 374)
PBA Controls PBA Controls
(n = 265) (n= 413) (n = 134) (n = 240)
Employed/work for pay 34 42 45 51
Workplace absenteeism 24b 12 10 9
Workplace presenteeism (impairment while at work) 39 33 44b 27
Work productivity loss (overall work impairment) 50b 38 48b 32
Overall activity impairment (daily activities other than work) 58b 41 47 42
PBA pseudobulbar affect
a Other than employment rate, which is expressed as a percentage of respondents, scores are expressed as impairment 
percentages, with higher numbers denoting greater impairment; absenteeism: percentage of work time missed due to your/
your patient’s health problem; presenteeism: percentage of impairment while working due to your/your patient’s health 
problem; overall work impairment: percentage of overall work impairment (absenteeism plus presenteeism); overall activity 
impairment: percentage of activity impairment other than work due to your/your patient’s health problem
b Significant difference at P < 0.05, tested with disease severity adjustments; work productivity score (combination of 
absenteeism and reduced work productivity)
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the previous week including frustration (48% 
vs. 23%), feeling like a burden to those around 
them (35% vs. 13%), irritation (34% vs. 15%), 
feeling isolated (30% vs. 9%), and anger (26% 
vs. 12%) (P < 0.05 for all).
The survey also asked PBA group respondents 
(no controls) a series of customized questions 
specific to the frequency and severity of 
involuntary laughing and crying episodes 
and the degree to which these episodes were 
burdensome or disrupted specific life activities. 
PBA group respondents were first asked, “Have 
you [has the patient you care for] experienced 
involuntary episodes of crying and/or laughing 
that were exaggerated or even contrary to how 
you [they] felt at the time?” A total of 280 PBA 
Table 6  Impact of PBA group assignment and depressiona on SF-36 scores; MANOVA results 
SF-36 domain PBA Depression Interactionb,e Direction of PBA impactf
(CNS-LS ≥13)b,c (CES-D10 ≥10)b,d
Physical functioning 4.7, 0.031, Yes 40.8, <0.0001, Yes 0.2, 0.651, No Reduces (depression does 
not change PBA impact)
Role physical 10.5, 0.001, Yes 57.7, <0.0001, Yes 11.5, 0.001, Yes Reduces (depression lessens 
impact)
Bodily pain 1.9, 0.169, No 73.6, <0.0001, Yes 1.3, 0.259, No No impact
General health 9.7, 0.002, Yes 51.8, <0.0001, Yes 0.7, 0.393, No Reduces (depression does 
not change PBA impact)
Vitality 5.7, 0.017, Yes 115.9, <0.0001, Yes 1.5, 0.228, No Reduces (depression does 
not change PBA impact)
Social functioning 22.5, <0.0001, Yes 87.9, <0.0001, Yes 3.3, 0.07, No Reduces (depression does 
not change PBA impact)
Role emotional 34.3, <0.0001, Yes 45.6, <0.0001, Yes 12.2, 0.001, Yes Reduces (depression lessens 
impact)
Mental health 31.2, <0.0001, Yes 77.9, <0.0001, Yes 4.6, 0.033, Yes Reduces (depression lessens 
impact)
Physical component score 1.0, 0.315, No 45.9, <0.0001, Yes 0.1, 0.812, No No impact
Mental component score 38.8, <0.0001, Yes 69.3, <0.0001, Yes 9.9, 0.002, Yes Reduces (depression lessens 
impact)
CES-D10 Center for Epidemiologic Studies depression scale 10-item short form, CNS-LS Center for Neurologic Study 
lability scale, PBA pseudobulbar affect, SF-36 36-item short form health survey
a Depression defined by score of 10 or greater on the CES-D10
b The first number in each cell is the F value, followed by the probability of larger F value, and whether the impact of the 
factor SF-36 item score is significant (yes/no)
c Assesses whether PBA group assignment had a significant impact (main effect) on SF-36 score
d Assesses whether the presence of depression (CES-D10 >10) had a significant impact (main effect) on SF-36 score
e Indicates whether there is significant interacting effect of depression on the effect of PBA group assignment
f Indicates whether assignment to the PBA group has an effect to increase or reduce the SF-36 item score. If an interaction is 
present, the statement in parentheses indicates the effect of the interaction, i.e., whether the presence of depression augments 
or reduces the impact of PBA group assignment on the SF-36 item score
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group respondents (70.7% weighted for relative 
proportions of the underlying conditions within 
the total US population) answered “yes” to this 
question (83.6% [weighted] for respondents 
with a CNS-LS score ≥21). These percentages are 
somewhat lower than the estimated diagnostic 
accuracy of a CNS-LS score of 13 or greater for 
PBA (as validated in patients with ALS and MS), 
but are not surprising given that some patients 
with PBA may have poor insight into their 
symptoms, and some patients and caregivers 
may not characterize their symptoms using this 
specific definition.
Of those acknowledging involuntary or 
exaggerated laughing/crying, 58% said that the 
episodes were extremely (9%), very (16%), or 
somewhat (33%) burdensome to them/their 
patient. The perception of burden correlated 
with laughing/crying episode frequency. In 
patients describing their episodes as extremely 
or very burdensome, mean episode frequencies 
for the past week were 8.8 for crying and 
4.6 for laughing compared with 2.8 and 2.7, 
respectively, for respondents describing their 
episodes as somewhat or not burdensome 
(P < 0.05 for both laughing and crying 
frequency). When these respondents were 
asked to indicate how much they agreed with 
certain statements surrounding their/their 
patient’s laughing and crying episodes, given 
five possible response choices ranging from 
“strongly disagree” to “strongly agree”, 60% 
said (“somewhat” or “strongly agreed”) that 
they/their patient feel(s) embarrassed when the 
Extremely often
Not very often
Spending time with friends and family 7%22%29%21%12%8%
Social activities and other leisure pursuits 15%15%37%15%9%8%
Interacting with nurses or other healthcare professionals 14%25%28%15%8%9%
Talking on the telephone 12%22%35%16%7%8%
Going to the movies 31%23%20%11%9%6%
Shopping 14%26%28%18%8%7%
Participating in group community activities 24%18%30%13%6%9%
Dining out 16%27%30%14%6%7%
Work or professional activities 41%19%15%14%3%9%
Participating in rehabilitation therapy 40%22%15%10%5%8%
Driving a car 30%28%23%8%6%5%




Does not apply to me
% PBA respondents
Fig. 3  Interference of laughing and crying episodes with patient function. Percentage of PBA group respondents selecting 
the given option in response to the following question, “Please indicate, how often you would say the episodes of involuntary 
crying and/or laughing interfere with your [your patient’s] participation in each of the following activities. If you [your 
patient] do [does] not participate in an activity, please select ‘Does not apply to me [him/her].’” This question was completed 
only by PBA group respondents who also answered “yes” to the question, “Have you [has the patient you care for] ever 
experienced involuntary episodes of crying and/or laughing that were exaggerated or even contrary to how you [he/she] felt 
at the time?” PBA pseudobulbar affect
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episodes occur, 58% said that they/their patient 
feel(s) withdrawn from those around them, 
51% said that their/their patient’s laughing/crying 
episodes are a problem for others, and 57% said 
that preventing the episodes would increase their/
their patient’s QOL. Thirty-four percent of these 
PBA group patients and 38% of these caregivers 
said that it was “very” or “extremely important” 
to them/their patient that the episodes of 
involuntary crying and/or laughing be treated.
PBA group respondents who acknowledged 
involuntary laughing and crying episodes 
were then asked to specify the degree to which 
the episodes interfered with participation in 
11 social or instrumental activities; available 
response choices were “never,” “not very often,” 
“somewhat often,” “very often,” “extremely 
often,” or “does not apply to me [him/her].”
From 19% to 41% of these respondents 
said that involuntary laughing or crying 
interfered at least somewhat often with each 
of the following activities: spending time with 
friends and family; social activities and other 
leisure pursuits; interacting with healthcare 
professionals; shopping; talking on the 
telephone; participating in group/community 
activities; dining out; work or professional 
activities; going to the movies; participating in 
rehabilitation therapy; and driving a car (Fig. 3). 
In addition, from 9.0% to 24.4% of these 
respondents said that involuntary episodes of 
laughing and/or crying contributed “a great 
deal” to or “were the main cause” of distressing 
life situations such as moving to a nursing home 
or supervised living (9%), quitting or being fired 
from a job (16%), getting a divorce or ending a 
Was the main cause









Not taking a vacation
 or traveling
00%
Getting a divorce or ending
a significant relationship
00%
Quitting or getting fired
from a job
00%
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or supervised living setting
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Contributed a great deal
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% PBA respondents
Average number 
of situations affected 
by PBA symptoms
1 or more 63%
2 or more 47%







Fig. 4  Interference with life situations. Percentage of PBA group respondents selecting the given option in response to 
the following question: “To what extent have your [your patient’s] involuntary episodes of laughing and/or crying ever 
contributed to the following life situations? Please select all situations that apply.” This question was completed only by 
PBA group respondents who also answered “yes” to the question, “Have you [has the patient you care for] ever experienced 
involuntary episodes of crying and/or laughing that were exaggerated or even contrary to how you [he/she] felt at the time?” 
PBA pseudobulbar affect
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significant relationship (21%), or the patient’s 
becoming housebound (24%) (Fig. 4).
DISCUSSION
This survey was designed to measure the 
burden of PBA across a large community sample 
of patients with predisposing neurological 
disorders. The results from validated scales 
suggest that PBA is associated with significant 
impairment in overall health status and social 
and occupational functioning compared with 
controls with the same primary neurological 
conditions but without PBA. Involuntary 
episodes of laughing and/or crying affected 
patient-rated QOL and QOR and were associated 
with considerable psychological distress. In 
response to nonvalidated, customized questions, 
most PBA group respondents who acknowledged 
involuntary and inappropriate episodes of 
laughing and crying said they/their patient felt 
embarrassed by the episodes, withdrawn from 
those around them, and that preventing these 
episodes would improve their/their patient’s 
QOL. Their responses to the customized 
questions suggest PBA can impact daily activities 
and social relationships, and in some cases, even 
contribute to such extreme events as becoming 
housebound, ending a significant relationship, 
or being placed in a nursing home.
Among the caregiver-specific measures, 
caring for a patient with presumed PBA (CNS-LS 
≥13) was associated with reduced caregiver 
work productivity and greater overall work 
impairment compared with caregivers for 
patients without presumed PBA (CNS-LS <13). 
Depression was common in caregivers (>70% 
had CES-D10 scores ≥10), and occurred with 
similar frequency in both groups.
No previously published studies, to the 
authors’ knowledge, have sought to assess the 
burden associated with PBA across multiple 
domains and in a variety of underlying 
conditions. Calvert et al. [8] investigated 
psychosocial correlates of PBA in stroke 
survivors with and without “emotionalism”. 
Patients with emotionalism were identified via 
the “House” criteria, which are composed of 
three questions asking whether patients had 
recently experienced excessive, unexpected, 
and uncontrollable crying or laughing episodes 
(essentially) consistent with PBA [29]. Stroke 
patients with “emotionalism” had significantly 
higher rates of simple depression, tension, 
social unease, irritability, other depression, 
general anxiety, lack of energy, loss of interest, 
and ideas of reference compared with stroke 
patients without “emotionalism”. The finding 
of a significantly higher rate of depression in 
patients with emotionalism is consistent with 
the present survey, which found a significantly 
higher prevalence of depressive symptoms in 
PBA group patients compared with controls, 
including in the subgroup with stroke.
Strowd et al. [11] published a retrospective 
chart review that assessed PBA prevalence and 
association with mood disorders and QOL in 
patients with movement disorders (n = 269), 
including PD (n = 168), essential tremor (n = 35), 
dystonia (n = 13), psychogenic movement 
disorders (n = 16), and other diagnoses (n = 28). 
As part of routine clinic assessments all patients 
had completed the CNS-LS, Beck depression 
inventory (BDI), and Parkinson’s disease 
questionnaire (PDQ-39), a 39-question, validated 
instrument that assesses eight dimensions of 
health-related QOL, including emotional well-
being [11, 30]. In that study, patients with 
PBA had significantly higher (worse) scores 
on the BDI and PDQ-39 emotional well-being 
subscores compared with those without PBA 
regardless of whether a CNS-LS threshold 
of 13 or greater or 17 or greater was used to 
define PBA. The association between PBA and 
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depression persisted even after removing BDI 
question 10 pertaining to episodes of crying. 
The relationship between PBA and depression 
in these patients is consistent with the CES-D10 
scale results in our study, suggesting significantly 
higher rates of depression in PBA group patients 
overall compared with controls, including 
the subgroup with PD. The higher PDQ-39 
emotional well-being subscores (including 
the items “depressed,” “isolated and lonely,” 
“weepy or tearful,” “angry or bitter,” “anxious,” 
“worried about the future”) [31] among 
the movement disorders patients in Strowd 
et al. [11] may also parallel our survey findings 
of increased depression, lower SF-36 mental 
component domain and summary scores, and 
increased psychological distress in PBA group 
patients versus controls.
Two other studies in patients with PD 
examined the relationship of PBA and 
depression; one (n = 131) found no association 
between Hamilton depression rating scale 
scores and a diagnosis of involuntary emotional 
expression disorder (IEED) [14]; while the 
other, which also included patients with other 
movement disorders (n = 387 PD patients; 
n = 332 other movement disorders), did show 
a significant association of depression and 
PBA in the total study population [10]. Both 
of these studies also found greater functional 
impairment in the unified Parkinson’s disease 
rating scale ADL section in patients with PBA 
(IEED); however, this association was considered 
more likely to be attributable to greater duration 
or severity of illness in these patients [10, 14].
Although previous studies have not examined 
differences in workplace function in patients 
with and without PBA, some findings may be 
relevant to the impaired work function observed 
in this survey. For example, patients with PBA 
have been shown to have reduced cognitive 
function in an MS population [32, 33] and 
in an ALS population [34], as well as reduced 
executive function in a stroke population [12], 
when compared with patients with the same 
underlying conditions but without PBA. Cognitive 
problems, in turn, have been correlated with 
unemployment in the MS population [35–37], 
and measures of executive dysfunction have 
been associated with unemployment in stroke 
patients [38]. In addition, a reported case study 
in a nonambulatory but full-time, employed 
patient with MS illustrates how the socially 
inappropriate and disruptive symptoms of PBA, 
such as “giggling or crying out during meetings,” 
may have substantial adverse impacts on work 
function, independently of the other symptoms 
of the underlying disease [39]. Indeed, in this 
survey 16% of PBA group respondents reported 
that inappropriate episodes of laughing/crying 
were the main cause of or contributed a great 
deal to job loss.
Based on VAS scores, uncontrollable laughter, 
tearfulness, or anger affected patients’ overall 
QOR with others to a significantly greater 
extent in the PBA group patients compared 
with controls. This result is consistent with PBA 
patient and caregiver ratings on customized 
questions in this survey regarding the specific 
impact of uncontrollable laughing/crying 
episodes on a range of day-to-day social 
activities and interpersonal interactions. Most 
remarkable of which are the 42%, 29%, and 
15% of respondents who reported that laughing/
crying episodes contributed at least “somewhat,” 
and 24%, 21%, and 9% who said that they 
contributed a “great deal,” or were “the main 
cause” of the patient becoming housebound, 
getting a divorce or ending a significant 
relationship, or being placed in a nursing 
facility/supervised living. Few other studies 
have examined the impact of PBA episodes on 
social function. A study of 92 patients with TBI 
reported that those with pathological laughter or 
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crying showed significantly greater impairment 
on social functioning exam scores [40] compared 
with those who did not have these symptoms [9]. 
Conversely, a matched case-control study (n = 24) 
of neurobehavioral correlates of pathological 
laughing and crying in patients with MS did not 
show differences between groups in the social 
dysfunction component of the general health 
questionnaire; however, patients in this sample 
were said to be severely disabled, and general 
health questionnaire social dysfunction items 
were commonly endorsed by both case and 
control groups in the study [32].
Interpretation of the survey results must 
consider several limitations. Although the 
authors attempted to adjust for differences 
in underlying disease severity and some 
demographic variables, these and a variety of 
other factors could still have affected survey 
results. To control for potential between-group 
differences in underlying disease severity, 
weighting factors were applied to the results 
based on respondent self-assessments. Patient/
caregiver assessments of overall disease severity 
were considered to be a valid severity measure 
based on positive correlations with the disease-
specific severity scale scores in four of the six 
evaluated disease states. That said, the simplistic 
range of responses (mild, moderate, severe) on 
global ratings may not have captured more 
subtle severity differences that may exist among 
patients or broadly and reliably reflect more 
objective disease severity measures. The extent 
to which the presence of PBA, depression, or 
other associated symptoms may have impacted 
self-assessed severity is not known.
Likewise, demographic weightings were used 
to adjust for between-group differences in age 
and gender; however, no adjustments were 
made to account for the potential influence 
of other demographic factors, such as patient/
caregiver education, socioeconomic status, 
the patient’s living situation, the presence of 
a caregiver, or the patient’s relationship to the 
caregiver. The relative proportion of caregivers 
and patient respondents was not uniform 
among the individual disease groups, and ALS 
and AD patients were underrepresented in 
the sample, precluding a thorough evaluation 
of potential differences in survey measures 
in these disease states. In addition, the use of 
caregivers as patient proxies, although allowing 
a more representative patient sample, may have 
introduced additional bias.
To improve generalizability and ensure 
that the contribution of PBA responses from 
individual disease groups reflected the population 
at large, the overall results were additionally 
weighted to reflect the relative proportions of the 
primary neurological conditions, and estimated 
prevalence of PBA within each condition, in the 
total US population.
Another important limitation is that 
patients in this trial were not required to 
have been clinically diagnosed with PBA to 
be included in the survey, with determination 
of PBA based exclusively on a CNS-LS score 
of 13 or greater. While the CNS-LS had been 
validated as a measure of PBA symptoms in 
ALS and MS at the time of this survey, and 
is frequently used as a screening instrument, 
it is not diagnostic for PBA. Subsequent to 
this survey, a validation study was published 
in patients with PD, showing a sensitivity of 
0.93 and a specificity of 0.51 for symptoms or 
diagnosis of IEED (a diagnosis similar to PBA) 
with a CNS-LS threshold of 11; the CNS-LS 
showed poor discriminant validity for IEED 
in these patients, due to high correlation 
with depressive symptoms [41]. The CNS-LS 
has not been validated in patients with other 
underlying neurological conditions. The 
CNS-LS threshold of 13 used to determine the 
PBA group in this survey was based on the 
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validation studies in ALS and MS and meant 
to ensure the inclusion of patients with more 
moderate PBA symptoms. The lower specificity 
of the CNS-LS in MS and PD suggests that at 
least some patients were assigned to the PBA 
group who did not have clinical PBA. It is 
noteworthy, however, that 71% of PBA group 
respondents did answer “yes” to the survey 
question, “Have you [has the patient you 
care for] experienced involuntary episodes of 
crying and/or laughing that were exaggerated 
or even contrary to how you [they] felt at 
the time?” consistent with the presence of 
PBA; another 10% answered this question 
as “unsure” and 19% said “no,” indicating a 
potential lack of PBA diagnosis or at least a 
lack of awareness of PBA symptoms. Future 
studies should consider use of a “gateway” 
question such as this one or short diagnostic 
interview to ascertain PBA.
As noted above, a positive association 
between CNS-LS scores and depressive symptoms 
has been observed in patients with ALS and PD 
[11, 15, 41], and the prevalence of depression 
was also significantly higher in PBA group 
patients (87%) than controls (56%) in this study. 
Depression can impact burden measures such 
as the SF-36 [28]. To address this limitation, a 
post hoc MANOVA analysis was conducted. The 
results suggested that both depression and PBA 
group assignment separately impacted SF-36 
domain and component scores, with depression 
exerting a significant negative impact on all 
SF-36 domains, PBA group assignment exerting a 
significant negative impact on all SF-36 domains 
except bodily pain and the physical component 
score, and an interaction of depression and PBA 
group assignment lessening the impact of PBA 
group assignment on the SF-36 subscales of role 
physical, role emotional, mental health, and 
the mental health component scores. While it 
may seem counterintuitive that an interaction 
of depression with PBA group assignment would 
serve to lessen the negative impact of PBA 
group assignment on SF-36 subscales, this could 
perhaps be explained by potential difficulties of 
the CNS-LS to discriminate depression reliably 
from PBA, i.e., some depressed patients may 
have been categorized as PBA when, in fact, they 
only had depression.
The association of PBA group assignment 
and depression is also of clinical relevance in 
that patients with PBA may be misdiagnosed 
with depression on the basis of their PBA 
episodes [41, 42]. Indeed, among the minority of 
survey respondents who had spoken with their 
physicians and received a diagnosis for their 
involuntary episodes of laughing and/or crying 
(n = 63), 23% were diagnosed with depression, 
and another 5% with bipolar disorder; 1.1% were 
given a diagnosis of either PBA or emotional 
lability. In the process of testing, evaluating 
and validating the CNS-LS scale in ALS patients, 
Moore et al. [15] found there was a significant 
relationship between the crying/tearfulness 
subscale of the CNS-LS and BDI scores; however, 
variability in depression scores accounted for 
only 6% of the variance in CNS-LS scores. While 
depression and PBA may occur alone or together, 
it is important to evaluate patients with crying 
episodes to ensure that neither is overlooked.
Finally, the nonlongitudinal design of this 
survey did not allow evaluation as to whether 
difficulties with social and occupational function 
develop coincidently with the emergence of PBA 
symptoms or are alleviated with PBA treatment.
CONCLUSION
This study found that patients and primary 
caregivers of patients with presumed PBA 
(CNS-LS ≥13) have a significantly increased 
burden of illness compared with patients and 
caregivers of patients with the same underlying 
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neurological conditions but without PBA. PBA 
group patients showed significantly greater 
impairment on measures of general health 
status, occupational and social function, and 
a significantly higher incidence of depressive 
symptoms than controls, both across and 
within primary neurological disease groups. 
Inappropriate laughing/crying episodes were 
associated with feelings of embarrassment, 
frustration, and the potential for withdrawal 
and isolation. Additional research is warranted 
to confirm these findings, further characterize 
the prevalence and impact of PBA, and improve 
awareness and recognition of this disorder.
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